Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT01769378
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT01769378
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Croatia, Mexico, Romania, Slovenia, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT01769378. Randomized; triple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2015-10-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
- Acronym
- AWARD-8
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01769378- Content hash
1709b49cee292f07013e35a84e76f54380077daaa2bff2a11e91e6d16e8b0fd2